Document is current
Any future updates will be listed below
-
Authors
Luo, Wei-Chi
Mei, Shi-Qi
Huang, Zi-Jian
Chen, Zhi-Hong
Zhang, Yi-Chen
Yang, Ming-Yi
Liu, Jia-Qi
Xu, Jing-Yan
Yang, Xiao-Rong
Zhong, Ri-Wei
Tang, Li-Bo
Yin, Lin-Xi
Deng, Yu
Peng, Ying-Long
Lu, Chang
Chen, Bao-Long
Ke, Dong-Xian
Tu, Hai-Yan
Yang, Jin-Ji
Xu, Chong-Rui
Wu, Yi-Long
Zhou, Qing http://orcid.org/0000-0002-0478-176X
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82102808, 82373349)
The Southern Medical University’s Young Talents Climbing Program for Science and Technology Development (G623281109)
Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (2017B030314120)
Guangdong Provincial People's Hospital Young Talent Project (KY0120220136)
- License Information
-
More Information
Article History
Received: 4 February 2024
Accepted: 27 March 2024
First Online: 2 April 2024
Declarations
:
: The study was approved by the Ethics Committee at Guangdong Provincial People's Hospital, No. GDREC2019304H(R1). All patients were informed of the study and consented to the enrollment.
: Not applicable.
: Prof. Y.L Wu reports grants and personal fees from AstraZeneca, BMS, Pfizer; and personal fees from Boehringer Ingelheim, Eli Lilly, Hengrui, MSD, Sanofi, Roche, outside the submitted work. Prof. Q. Zhou reports honoraria from AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, and Sanofi outside the submitted work. The other authors have no competing interests to declare.
